# 1. Financial Performance ## A. Key Figures * **Q2 FY26 Revenue:** **₹130 Cr** (-16% YoY, -1% QoQ) * **H1 FY26 Revenue:** **-12% YoY** (Domestic: further impacted by weather and regulation) * **Gross Margin Expansion:** **+500 bps** driven by product mix; long-term target of **50–52%** reiterated * EBITDA Margin: significantly higher than 26–27% guidance * **Contract Assets Increase:** **₹450 Cr** due to deferred customer deliveries * **Trade Working Capital:** **113 days** of sales * **Effective Tax Rate (ETR):** Expected **22–23%** over next 2–3 years ## B. Revenue Trends * **Resilient Growth Trajectory:** Despite a sharp YoY decline due to a high base and external disruptions, the company continues to outperform the industry with an H1 3-year CAGR of **8%**. * **Demand & Supply Normalization:** Increasing volumes and stable input prices are helping rebalance supply chain inventories amid easing market pressures. * **Cost Investment Phase:** Elevated overheads in Pharma reflect ongoing capability build-up and higher people costs during strategic investment phase. ## C. Gross Margin * **Margin Strength on Mix & Efficiency:** Gross margin expanded significantly on favorable product mix and operating improvements, with management affirming long-term sustainability of **50–52%**. * **Pharma Profitability Pressures:** PBT margins softened slightly due to one-off waste processing costs and **unfavorable product mix**, despite stable gross margins. ## D. EBITDA Margin * **Outperformance with Discipline:** EBITDA margins exceeded guidance range on strong mix tailwinds, though full-year outlook remains unchanged, signaling conservative guidance posture. ## E. Balance Sheet * **Accounting-Driven Asset Shift:** Increase in contract assets reflects revenue recognition under long-term contracts, not inventory buildup—driven by **deferred large deliveries**, not demand weakness. * **Revenue Recognition Clarity:** Revenue is recorded upon production for specific customer orders; contract assets represent unbilled receivables aligned with H2 delivery schedules. ## F. Cash Flow * **Working Capital Pressure Expected to Ease:** Elevated trade working capital at **113 days** reflects current market dynamics, with improvement anticipated as deliveries resume and conditions stabilize. * **Delivery Timeline in Sight:** Deferred contract asset deliveries expected over the **next 1–2 quarters**, supporting near-term cash flow normalization. --- # 2. Segment & Product Performance ## A. Key Figures * **Domestic Revenue:** **-5%** H1 FY26 YoY * **Pharma Business Revenue:** **+54%** QoQ YoY · **doubled** in H1 YoY * **Biologicals Revenue (PHC):** **$10–12 Mn** annualized * **Plant Healthcare Revenue:** **$10–12 Mn** annualized ## B. AgChem Exports * **Planned Export Softness:** AgChem export decline driven by **customer-led inventory balancing** and weak global demand, consistent with company guidance and seasonal patterns. * **Recovery Timing:** Export growth expected to rebound in **Q4 FY26**, delayed from Q3 due to seasonal delivery lags and ongoing destocking, particularly in the U.S. market. * **Market Context:** U.S. destocking is broad-based, with peer performance indicating underlying demand resilience and potential for near-term tailwinds. ## C. Domestic Business * **Weather-Driven Headwinds:** Domestic performance weakened in Q2 due to **erratic and excessive rainfall**, disrupting Kharif season momentum despite strong sowing and favorable monsoon onset. * **Regulatory & Demand Pressure:** Demand further dampened by **abrupt regulatory actions in biologicals**, compounding challenges from liquidity constraints and elevated channel inventories. * **Innovation Momentum:** Strong new product pipeline with **three brands launched in H1**, three more expected by year-end, and **20+ in development**, supporting long-term competitiveness. * **H2 Recovery Signal:** Early signs of improvement in domestic demand, with favorable Rabi prospects supported by healthy reservoir levels. ## D. Pharma & CDMO * **Robust Pharma Growth:** Pharma platform delivered **doubling of H1 revenue** on the back of new client wins and global business development expansion. * **Strategic Platform Build:** Continued investments in talent, processes, and assets to advance fully integrated **CRDMO platform**, despite biotech funding and geopolitical headwinds slowing proposal conversion. * **Commercial Diversification:** New products are **not fully agri-focused**, reflecting successful diversification of the CSM business into adjacent high-growth chemistries. * **Emerging Opportunities:** Active pursuit of **second-source commercial programs** via technology transfer, with **5–6 electronic chemicals products now commercialized** and more in pipeline. ## E. Biologicals * **Strategic Scale via Acquisition:** PHC acquisition established PI as **one of India’s largest biologicals players by portfolio and revenue**, anchored by a proprietary peptides platform. * **High-Growth, Investment-Phase Business:** Biologicals growing at **double-digit CAGR** over five years; current focus is on **scaling distribution and label expansion**, not margin optimization. * **Revenue Trajectory:** Biologicals revenue expected to **scale significantly from FY26 onward**, with acceleration anticipated in FY27. * **Long-Term Margin Target:** Management acknowledges path to **~25% EBITDA margin** over time, though profitability will lag revenue growth during investment phase. --- # 3. Order Book & New Products ## A. Key Figures * CSM Order Book: $1.25 Bn (as of Q2 FY26) · $1.25 Bn (discussed amount) * **New Molecule Launches:** **5** (H1 FY26) · **8–10 expected** (full fiscal) ## B. CSM Order Book * **Robust Backlog:** CSM maintains a substantial **$25 Bn** order book with no near-term visibility on fiscal year allocation, indicating long-duration demand. ## C. Product Launches * **Accelerated Commercialization:** Strong double-digit growth in new products driven by expanded launches, including diversification into **non-AgChem** electronic and specialty chemicals. * **Sustained Launch Cadence:** Company on track to commercialize **5 to 6 additional products in H2**, maintaining a balanced mix across agrochemical and specialty segments. ## D. Pipeline Progress * **Pharma CDMO Momentum:** Pipeline includes **six late-stage programs** (Phase II/III), with no current revenue contribution but significant long-term potential as projects mature. * **NCE Milestone Ahead:** PI progressing toward **first NCE registration in India**, supported by active field trials and internal R&D. * **Electronic Chemicals R&D Strength:** Strong pipeline underpins scale-up efforts, signaling strategic growth focus beyond traditional segments. --- # 4. Capacity & Investment ## A. Manufacturing Sites * **Headline:** One of two upcoming plants commissioned, with dedicated capacity for agrochemicals to support new product ramp-up and expanded output. * **Headline:** Electronic chemicals infrastructure advanced, featuring one plant near commissioning and a multi-product facility in place. ## B. Capability Building * **Headline:** Pharma business in active investment phase, incurring higher overheads from capability, talent, and process development ahead of scale leverage. ## C. R&D Centers * **Headline:** Biological R&D footprint expanded with new **Hyderabad centre**, complementing **Seattle hub** and accelerating product development in key markets. * **Headline:** Innovation strategy reinforced through **partnerships with crop solution companies** and targeted investments across US, Brazil, Europe, Mexico, and India. --- # 5. Customer & Market Expansion ## A. Client Onboarding * **Accelerating Pharma Engagements:** Onboarding of **two pharma clients** is underway, with the company advancing to the next phase of its engagement strategy. * **Pipeline Momentum:** Expansion efforts continue with **four large pharmaceutical clients** in active discussions, underscoring traction beyond current onboarding. * **Q4 Recovery Signal:** Anticipated rebound in activity is based on customer feedback and tentative timelines, pointing to improving demand visibility. ## B. Global Geographies * **Strategic Transformation:** Firm is evolving from an ag sciences player into a **diversified life sciences enterprise**, with growth engines in Ag Sciences, Pharma CRDMO, and Specialty Chemicals. * **Biologicals Execution:** Global biologicals business is on track, with progress in **new product development**, **US and Brazil market expansion**, and **regulatory filings for peptides and label extensions**. * **Scalable Global Model:** International biologicals expansion is expected to replicate strong growth patterns once development and regulatory milestones are achieved. * **Platform Positioning:** PI Industries is leveraging its **cutting-edge peptide platform** to capture leadership in emerging life sciences markets. ## C. Strategic Partnerships * **Structural Market Shifts:** Long-term demand for next-gen crop technologies is being driven by sustainability, resistance challenges, and rising global demand for food, fibre, and biofuels. * **Industry Consolidation & Collaboration:** Global agchem players are deepening value chain partnerships to enhance resilience and optimize costs amid regulatory complexity. * **Inorganic Growth Posture:** Company is actively assessing **domestic and international technology-led acquisition opportunities**, remaining opportunistic on strategic moves, including in light of FMC’s exit from India. --- # 6. Regulatory & Market Risks ## A. Key Figures * Crop Damage: Over 1.2 million acres affected in Punjab and Maharashtra due to flooding ## B. Approval Delays * **Regulatory Setbacks Resolved:** Domestic biologicals sales ban lifted and onboarding progressing; commercial resumption expected from Q4 onward. * **Transitory Disruption:** Biologicals segment challenges deemed temporary, though state-level approval delays continue to weigh on agri revenue. ## C. Geopolitical Impact * **Sector-Wide Downcycle:** Global crop protection industry under pressure from destocking, Chinese overcapacity, low commodity prices, and weather-related spray reductions. * **Market Share Opportunity:** Potential exit of global players (e.g., FMC) could benefit domestic agrochemical firms amid consolidation trends. * **Policy Uncertainty:** U.S. tariffs not currently disruptive, but broader regulatory and trade uncertainty is delaying strategic decisions in agchem and pharma. --- # 7. Guidance & Outlook ## A. Key Figures * **FY26 Revenue Guidance:** **Mid-single-digit growth** (unchanged) · **H1 Revenue Decline:** **3% to 5%** (global innovators) * **Biologicals Growth Outlook:** **Three- to four-fold expansion** long-term · **Domestic CAGR:** **>25%** (historical) ## B. FY26 Revenue View * **Guidance Unchanged, H2-Centric Recovery:** Full-year outlook hinges on **modest recovery in Q4 FY26**, with no revision despite weak H1, as export momentum and improved agro conditions are expected to offset earlier declines. * **Limited Near-Term Visibility:** FY27 order book and CSM growth remain unguided due to **low visibility**, though offtake signals emerging from Q4 FY26 provide foundational confidence. ## C. H2 Recovery * **Cautious Volume-Led Rebound Expected:** Global agchem recovery anticipated in H2 FY26, supported by **normalized consumption and restocking cycles**, though full recovery not expected before mid-2026. * **India Recovery Drivers Identified:** Improved rabi acreage (rice, corn) and favorable reservoir levels expected to lift domestic demand in H2, offsetting Q2 crop losses from erratic monsoon. * **CSM Recovery Phased:** Q3 to reflect continued softness, with **growth resuming from Q4 FY26**, though quarterly projections remain speculative. ## D. Long-Term Growth * **Structural Growth Intact Amid Headwinds:** Long-term outlook preserved across agchem and pharma, with confidence in returning to **higher growth trajectory** as climatic and macro challenges ease. * **Biologicals as Key Growth Engine:** Positioned for **sustained double-digit expansion** over 5–10 years, with multiple product registrations underway and scaling expected by **FY28–FY29**. * **Pharma Business Nearing Profitability:** Investment phase to last ~1 more year, with **positive EBITDA expected within 12 months**, despite biotech funding headwinds.